William Blair initiated coverage of Aktis Oncology (AKTS) with an Outperform rating. The company is positioned to become a radiopharmaceuticals leader by using miniproteins to address novel targets within the modality, the analyst tells investors in a research note. The firm believes Aktis’ approach could allow the company to capture a “material proportion “of the radiopharmaceuticals market, which it estimates to be $35B.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTS:
- Aktis Oncology appoints Gormley as independent director of Board of Directors
- Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target
- Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright
- Aktis Oncology announces FDA clearance of AKY-25191 trial
- 3 Best Stocks to Buy Today, 3/9/2026, According to Top Analysts